Idia AS has successfully completed the first clinical trial with its proprietary kiwifruit extract.

Idia AS has succesfully completed the first clinical trial with its proprietary kiwifruit extract. The headline results from this randomized, double-blinded and placebo-controlled cross-over study in 50 subjects gives evidence of a clinically relevant reduction in systolic blood pressure in the target population.

The extract will now enter into the next step of the clinical development program.

For further information, please contact the CEO at Idia, Ole Peter Nordby at op@idia.no.

Featured Posts
Recent Posts
Archive
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square